Together with azacitidine or decitabine, or reduced-dose cytarabine in newly diagnosed AML aged ≥ seventy five years or with co-morbidities that preclude the use of intense induction chemotherapy Name your collection: Identify need to be under people Pick a collection: Not able to load your selection resulting from an mistake https://directivepublications.org/journal-of-leukemia-research/